Skip to content
★ Sign in to follow
邵

邵俊斌

Board Director
Director
之江生物
Total declarations
4
Company
1
▲ Purchases (4 ops.)
€277k
▼ Sales (0 ops.)
—

Latest filing published 26 Jan 2022 for 之江生物, €65k.

Filing timeline

BuySale
邵俊斌

Insider track record

Disclosed buys
4
Disclosed sells
0
Signal history

Closed purchases

Market purchases
4
Positive at T+90
25%
Median T+90
-17.3%

Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 26 Jan 2022 · 1747 days ago · €65k
    -21.4%
    Entry CN¥43.60 · Close at T+365 CN¥34.26
  • Filed 19 Jan 2022 · 1754 days ago · €81k
    -35.6%
    Entry CN¥53.60 · Close at T+365 CN¥34.50
  • Filed 03 Nov 2021 · 1831 days ago · €64k
    -19.3%
    Entry CN¥47.62 · Close at T+365 CN¥38.41
  • Filed 13 Sept 2021 · 1882 days ago · €67k
    -21.6%
    Entry CN¥50.72 · Close at T+365 CN¥39.76

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

邵俊斌: trading record in brief

邵俊斌 is a declared insider of 之江生物 (board member), with filings sourced from SSE / SZSE (CSRC). In total, 4 filings cover trades dated from 13 September 2021 to 26 January 2022.

On the market, this insider has only ever bought: 4 purchases, €277k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2022 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €66k. The 4 purchases reviewed show no overlap with other insiders buying the same stock within a month. After 4 purchases with a full 90-day history, the hit rate stands at 25% and the median 90-day move at -17.3%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 26 January 2022, reports an open-market purchase of €65k in 之江生物. Most trades are made public on the day they happen. This delay matters because a trade only becomes useful information once it is public. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Companies and markets linked to 邵俊斌

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations4 total
  • ▲
    董事Executives之江生物
    464,790 CNY9SSE
    10,000 shares23.5% of flowA股XSHGSSE:173000005250145760
    Canonical exit: 26 Apr 2022 (T+90)
  • ▲
    董事,核心技术人员Executives之江生物
    581,980 CNY10SSE
    10,000 shares29.2% of flowA股XSHGSSE:173000005229776900
    Canonical exit: 19 Apr 2022 (T+90)
  • ▲
    董事,核心技术人员Executives之江生物
    475,400 CNY9SSE
    10,000 shares23.2% of flowA股XSHGSSE:173000005038718900
    Canonical exit: 1 Feb 2022 (T+90)
  • ▲
    董事,核心技术人员Executives之江生物
    509,700 CNY9SSE
    10,000 shares24.2% of flowA股XSHGSSE:173000004826181540
    Canonical exit: 12 Dec 2021 (T+90)

4 of 4 declarations